Novo Nordisk Invests $4.1 billion to Expand US Manufacturing, Improving the Efficacy of Genetic Medicines & more

Improving the Efficacy of Genetic Medicines

Shawn Davis, CEO of Liberate Bio, shares some insights into the world of drug discovery, development, and delivery, as well as process optimization.

Experts Discuss Serious Adverse Events for GLP-1 Medications

Potential concerns surrounding GLP-include pancreatitis, pancreatic cancer, colorectal cancer, suicide and other phycological effects, and thyroid cancer.

Welcome to the Era of the AI Smartphone

Apple and Google are getting up close and personal with user data to craft memos, summarize documents and generate images.

Novo Nordisk announces 4.1 billion USD investment to expand US manufacturing capacity adline

Novo Nordisk today announced plans to invest 4.1 billion US dollars (approx 27 billion Danish kroner) to build a second fill and finishing manufacturing facility in Clayton, North Carolina, and grow its ability to produce current and future injectable treatments for people with obesity and other serious chronic diseases.

Nicholas Saraceno on LinkedIn

Thank you for the insightful chat, Fran Gregory, PharmD, MBA! In regard to the pipeline, she noted that “It’s exciting because some of the products that I was extremely concerned about 10 years ago from a spend perspective and an economic perspective are now seen in the pipeline as biosimilars,” speaking volumes to how innovative the space has grown to become, while also keeping in mind biosimilars’ potential for placement on formularies.

Have news you want us to share in Pharma Pulse? Reach out to Social

Media Editor Miranda Schmalfuhs

Leave a Reply

Your email address will not be published. Required fields are marked *